Cancer Institute of NJ Adds to its Staff

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jersey welcomed Joseph Aisner, MD, as its new associate director of clinical science, and added four new physician/scientists to its staff.

NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jerseywelcomed Joseph Aisner, MD, as its new associate director of clinicalscience, and added four new physician/scientists to its staff.

Dr. Aisner will also serve as chief of the Division of MedicalOncology and professor of medicine and environment and communitymedicine. He was recruited from the University of Maryland wherehe was chief of medical oncology and director of the Cancer Center.

Joseph Germino, MD, and Eric H. Rubin, MD, have joined the Instituteas assistant professors of medicine. Dr. Germino comes from YaleUniversity School of Medicine and Dr. Rubin from Dana-Farber andHarvard Medical School.

James Stephen Goydos, MD, of the University of Pittsburgh, isa new instructor of surgery, and Thomas Joseph Kearney, MD, ofthe University of Chicago, is assistant professor of surgery.

Established in 1990, The Cancer Institute of New Jersey is a partnershipof four New Jersey hospitals and medical centers, the Universityof Medicine and Dentistry of New Jersey (UMDNJ), and the UMDNJ-RobertWood Johnson Medical School.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content